These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30616098)

  • 1. Identification of a pyrimidinetrione derivative as the potent DprE1 inhibitor by structure-based virtual ligand screening.
    Gao Y; Xie J; Tang R; Yang K; Zhang Y; Chen L; Li H
    Bioorg Chem; 2019 Apr; 85():168-178. PubMed ID: 30616098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virtual Screening of Small Molecular Inhibitors against DprE1.
    Zhang G; Guo S; Cui H; Qi J
    Molecules; 2018 Feb; 23(3):. PubMed ID: 29495447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.
    Neres J; Hartkoorn RC; Chiarelli LR; Gadupudi R; Pasca MR; Mori G; Venturelli A; Savina S; Makarov V; Kolly GS; Molteni E; Binda C; Dhar N; Ferrari S; Brodin P; Delorme V; Landry V; de Jesus Lopes Ribeiro AL; Farina D; Saxena P; Pojer F; Carta A; Luciani R; Porta A; Zanoni G; De Rossi E; Costi MP; Riccardi G; Cole ST
    ACS Chem Biol; 2015 Mar; 10(3):705-14. PubMed ID: 25427196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the
    Ezquerra-Aznárez JM; Degiacomi G; Gašparovič H; Stelitano G; Sammartino JC; Korduláková J; Governa P; Manetti F; Pasca MR; Chiarelli LR; Ramón-García S
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.
    Foo CS; Lechartier B; Kolly GS; Boy-Röttger S; Neres J; Rybniker J; Lupien A; Sala C; Piton J; Cole ST
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6451-6459. PubMed ID: 27527085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.
    Balabon O; Pitta E; Rogacki MK; Meiler E; Casanueva R; Guijarro L; Huss S; Lopez-Roman EM; Santos-Villarejo Á; Augustyns K; Ballell L; Aguirre DB; Bates RH; Cunningham F; Cacho M; Van der Veken P
    J Med Chem; 2020 May; 63(10):5367-5386. PubMed ID: 32342688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.
    Chikhale RV; Barmade MA; Murumkar PR; Yadav MR
    J Med Chem; 2018 Oct; 61(19):8563-8593. PubMed ID: 29851474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors.
    Piton J; Foo CS; Cole ST
    Drug Discov Today; 2017 Mar; 22(3):526-533. PubMed ID: 27666194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic molecules as DprE1 inhibitors: A patent review.
    Imran M; A S A; Thabet HK; Abida ; Afroz Bakht M
    Expert Opin Ther Pat; 2021 Aug; 31(8):759-772. PubMed ID: 33709862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DprE1--from the discovery to the promising tuberculosis drug target.
    Mikusová K; Makarov V; Neres J
    Curr Pharm Des; 2014; 20(27):4379-403. PubMed ID: 24245764
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Borthwick JA; Alemparte C; Wall I; Whitehurst BC; Argyrou A; Burley G; de Dios-Anton P; Guijarro L; Monteiro MC; Ortega F; Suckling CJ; Pichel JC; Cacho M; Young RJ
    J Med Chem; 2020 Mar; 63(5):2557-2576. PubMed ID: 31922409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a Chemical Inhibitor with a Novel Scaffold Targeting Decaprenylphosphoryl-β-D-Ribose Oxidase (DprE1).
    Matsunaga T; Monobe K; Aoki S
    Infect Disord Drug Targets; 2023; 23(5):e090323214508. PubMed ID: 36892121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel DprE1 inhibitors via computational bioactivity fingerprints and structure-based virtual screening.
    Hu XP; Yang L; Chai X; Lei YX; Alam MS; Liu L; Shen C; Jiang DJ; Wang Z; Liu ZY; Xu L; Wan KL; Zhang TY; Yin YL; Li D; Cao DS; Hou TJ
    Acta Pharmacol Sin; 2022 Jun; 43(6):1605-1615. PubMed ID: 34667293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents.
    Liu L; Kong C; Fumagalli M; Savková K; Xu Y; Huszár S; Sammartino JC; Fan D; Chiarelli LR; Mikušová K; Sun Z; Qiao C
    Eur J Med Chem; 2020 Dec; 208():112773. PubMed ID: 32898793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis.
    Makarov V; Neres J; Hartkoorn RC; Ryabova OB; Kazakova E; Šarkan M; Huszár S; Piton J; Kolly GS; Vocat A; Conroy TM; Mikušová K; Cole ST
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4446-52. PubMed ID: 25987616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis.
    Riccardi G; Pasca MR; Chiarelli LR; Manina G; Mattevi A; Binda C
    Appl Microbiol Biotechnol; 2013 Oct; 97(20):8841-8. PubMed ID: 24037308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase.
    Landge S; Mullick AB; Nagalapur K; Neres J; Subbulakshmi V; Murugan K; Ghosh A; Sadler C; Fellows MD; Humnabadkar V; Mahadevaswamy J; Vachaspati P; Sharma S; Kaur P; Mallya M; Rudrapatna S; Awasthy D; Sambandamurthy VK; Pojer F; Cole ST; Balganesh TS; Ugarkar BG; Balasubramanian V; Bandodkar BS; Panda M; Ramachandran V
    Bioorg Med Chem; 2015 Dec; 23(24):7694-710. PubMed ID: 26643218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and inhibition analysis of novel sulfur-rich 2-mercaptobenzothiazole and 1,2,3-triazole ligands against Mycobacterium tuberculosis DprE1 enzyme.
    Karan S; Kashyap VK; Shafi S; Saxena AK
    J Mol Model; 2017 Aug; 23(8):241. PubMed ID: 28744747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.
    Panda M; Ramachandran S; Ramachandran V; Shirude PS; Humnabadkar V; Nagalapur K; Sharma S; Kaur P; Guptha S; Narayan A; Mahadevaswamy J; Ambady A; Hegde N; Rudrapatna SS; Hosagrahara VP; Sambandamurthy VK; Raichurkar A
    J Med Chem; 2014 Jun; 57(11):4761-71. PubMed ID: 24818517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of DprE1 inhibitors for tuberculosis through integrated in-silico approaches.
    Dash S; Rathi E; Kumar A; Chawla K; Kini SG
    Sci Rep; 2024 May; 14(1):11315. PubMed ID: 38760437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.